Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors

Oncology Reports

Volumn 17, Issue 5, 2007, Pages 1155-1161

  Addeo, Raffaele ^a,b   Crisci, Stefania ^a   D'Angelo, Velia ^a   Vincenzi, Bruno ^c   Casale, Fiorina ^a   Pettinato, Guido ^a   Donofrio, Vittoria ^d   Boldrini, Renata ^e   Alaggio, Rita ^f   Collini, Paola ^g   Bertorelle, Roberta ^f   Di Tullio, Maria Teresa ^a   Caraglia, Michele ^h   Terenziani, Monica ⁱ   Lo Curto, Margherita ^j   Indolfi, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g National Tumour Institute   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

Apoptosis; BAX; Childhood; Germ cell tumors; p53; Prognosis

Indexed keywords

BAX PROTEIN, HUMAN; PROTEIN BAX; PROTEIN P53; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BIOSYNTHESIS; CHILD; FEMALE; GENETICS; HUMAN; IMMUNOCHEMISTRY; INFANT; MALE; METABOLISM; MUTATION; NEOPLASM; NEWBORN; PATHOLOGY; PHENOTYPE; PRESCHOOL CHILD; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

ADOLESCENT; BCL-2-ASSOCIATED X PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, P53; HUMANS; IMMUNOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MUTATION; NEOPLASMS, GERM CELL AND EMBRYONAL; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548567398     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.5.1155     Document Type: Article

References (28)

1. Schneider DT, Schuster AE, Fritsch MK, Calaminus G, Gobel U, Harms D, et al: Genetic analysis of mediastinal non-seminomatous germ cell tumors in children and adolescents. Genes Chromosomes Cancer 34: 115-125, 2002. (Pubitemid 34260603)
2. Bussey KJ, Lawce HJ, Himoe E, Shu XO, Suijkerbuijk RF, Olson SB, et al: Chromosomes 1 and 12 abnormalities in pediatric germ cell tumors by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet 125: 112-118, 2001. (Pubitemid 32448054)
3. Mullauer L, Gruber P, Sebinger D, Buch J, Wohlfart S and Chott A: Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 488: 211-231, 2001. (Pubitemid 32521033)
4. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
5. Yin C, Knudson CM, Korsmeyer SJ and Van Dyke T: BAX suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640, 1997. (Pubitemid 27087577)
6. Knudson CM, Tung KSK, Tourtellotte WG, Brown GA and Korsmeyer SJ: BAX-deficent mice with lymphoid hyperplasia and male germ cell death. Science 270: 96-99, 1995.
7. Yan W, Suominen J, Samson M, Jegou B and Toppari J: Involvement of Bcl-2 family proteins in germ cell apoptosis during development in the rat and pro-survival effect of stem cell factor on germ cells in vitro. Mol Cell Endocrinol 165: 115-129, 2000. (Pubitemid 30625190)
8. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969, 1997. (Pubitemid 27087710)
9. Yamamoto H, Itoh F, Fukushima H, Adachi Y, Itoh H, Hinoda Y, et al: Frequent Bax frameshift mutations in gastric cancer with high but not low microsatellite instability. J Exp Clin Cancer Res 18: 103-106, 1999. (Pubitemid 29232082)
10. Gascoyne RD, Krajewska M, Krajewsky S, Connors JM and Reed JC: Prognostic significance of BAX protein in diffuse aggressive non-Hodgkin's lymphoma. Blood 90: 3173-3178, 1997. (Pubitemid 27444213)
11. Tai YT, Lee S, Niloff E, Weiman C, Strobel T and Cannistra SA: Bax protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16: 2583-2590, 1998. (Pubitemid 28363020)
12. Krajewsky S, Blomquist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, et al: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478, 1995.
13. Hiroshima K, Toyozaki T, Iyoda A, Yusa T, Fujisawa T and Ohwada H: Apoptosis and proliferative activity in mature and immature teratomas of mediastinum. Cancer 92: 1798-1806, 2001. (Pubitemid 32952498)
14. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
15. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, et al: Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9: 767-773, 2003. (Pubitemid 36182613)
16. Wang XW and Harris CC: p53 tumor-suppressor gene: Clues to molecular carcinogenesis. J Cell Physiol 173: 247-255, 1997. (Pubitemid 27481139)
17. Sheikh MS and Fornace AJ Jr: Role of p53 family members in apoptosis. J Cell Physiol 182: 171-181, 2000. (Pubitemid 30022669)
18. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, et al: Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16: 2345-1349, 1998.
19. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al: Analysis of the p53/BAX Pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with the resected liver metastases. J Clin Oncol 5: 1364-1374, 1999. (Pubitemid 29220841)
20. Sturm I, Papadopulos S, Hillebrand T, Benter T, Luck HJ, Wolff G, et al: Impaired Bax protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer 87: 517-521, 2000. (Pubitemid 30639810)
21. Chou D, Miyashita T, Mohrenweiser HW, Ueki K, Kastury K, Druck T, et al: The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 88: 136-140, 1996. (Pubitemid 26196291)
22. Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR and Fiddes CA: Nucliotide sequence of bacteriophage phi X174 DNA. Nature 265: 687-695, 1977. (Pubitemid 8039446)
23. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
24. Peto R, Pike MC and Armitage P: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1-39, 1977. (Pubitemid 8018922)
25. Friess H, Lu Z, Graber HU, Zimmerman A, Adler G, Korc M, et al: BAX but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43: 414-421, 1998. (Pubitemid 28414925)
26. Burns FT and El-Deiry WS: The p53 pathway and apoptosis. J Cell Physiol 181: 231-239, 1999.
27. Harnois C, Demers M-J, Bouchard V, Vallée K, Gagné D, Fujita N, et al: Human intestinal epithelial crypt cell survival and death: Complex modulations of Bcl-2 homologs by Fak, PI3-K/Akt-1, MEK/Erk, and p38 signaling pathways. J Cell Physiol 198: 209-222, 2004. (Pubitemid 38139312)
28. Chresta CM, Masters JR and Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56: 1834-1841, 1996. (Pubitemid 26118219)